ArticleHealth science reports2026
A Disproportionality Analysis of β-lactam Antibiotic Related Blood and Lymphatic System Disorders Based on the FDA Adverse Event Reporting System Database.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: β-lactam antibiotics stand as the most profoundly impactful classes of antibacterial agents worldwide. Their widespread application has raised safety concerns over adverse events (AEs), such as blood and lymphatic system disorders (BLSDs). This study systematically evaluated and compared BLSDs associated with β-lactam antibiotics based on real-world data. Methods: We reviewed the FDA Adverse Event Reporting System (FAERS) database from 2004Q1 to 2025Q1. To explore the associations between 30 FDA-approved β-lactam antibiotics and BLSDs, 4 disproportionality analysis algorithms were utilized, including reporting odds ratio, proportional reporting ratio, bayesian confidence propagation neural network, and multi-item gamma poisson shrinker. Our analytical framework included subgroup analysis and sensitivity analysis, with the Weibull distribution applied to model the pattern of BLSDs over time. Results: The total number of reported BLSDs was 7872, accounting for 6.93% of all AEs related to β-lactam antibiotics. Notably, piperacillin/tazobactam, ceftriaxone, meropenem, cefazolin, cefepime, ceftazidime, ampicillin, oxacillin, cefotetan, and piperacillin produced strong signals of disproportionate reporting for BLSDs. Pyrexia, rash, and acute kidney injury emerged as the most frequently reported concurrent AEs. At the designated medical event level, several β-lactam antibiotics were found to be associated with agranulocytosis, hemolytic anemia, immune thrombocytopenia, pancytopenia, and other hematological AEs. With respect to the time-to-onset patterns, ceftriaxone, meropenem, and ceftazidime were classified as early failure modes, whereas cefepime, cefotetan, oxacillin, and piperacillin were categorized as wearout failure modes. Conclusions: This study revealed a notable association between β-lactam antibiotics and BLSDs, underscoring the importance of blood tests in clinical practice when β-lactam antibiotics are prescribed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.